Trials / Withdrawn
WithdrawnNCT02784067
A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- QOL Medical, LLC · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
S09A is a Phase 4, multicenter, randomized, double-blind, placebo-controlled, parallel study examining the efficacy and safety of a Sucraid (sacrosidase) Oral Solution in comparison to a placebo in 150-200 subjects with chronic diarrhea possibly attributable to sucrase deficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sucraid | Study drug |
| DRUG | Placebo | Sucraid placebo |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-05-26
- Last updated
- 2017-09-25
Source: ClinicalTrials.gov record NCT02784067. Inclusion in this directory is not an endorsement.